Literature DB >> 16911035

Night-to-night alterations in sleep apnea type in patients with heart failure.

R Tkacova1, H Wang, T D Bradley.   

Abstract

In patients with heart failure, apnea type can shift overnight from mainly obstructive to mainly central in association with reductions in PCO(2) and increases in periodic breathing cycle length, indicative of a fall in cardiac output. We hypothesized that the predominant apnea type could also vary from one night to another in association with alterations in PCO(2) and cycle length. We studied 12 men with heart failure in whom the predominant apnea type changed from one night to the next over periods of at least 1 month, and two groups with either predominantly obstructive or central sleep apnea (OSA or CSA) in whom apnea type remained stable over time. In patients with unstable apnea type (n = 12, duration between sleep studies 9.0 +/- 4.4 months), PCO(2) was significantly lower (37.6 +/- 1.6 mmHg versus 41.7 +/- 1.9 mmHg, P < 0.01), and cycle length significantly longer (61.9 +/- 3.4 s versus 51.0 +/- 1.9 s, P < 0.001) during nights with predominantly central than nights with predominantly obstructive apnea. In contrast, in both the stable central (n = 8, duration between sleep studies 11.9 +/- 5.3 months) and the stable obstructive (n = 8, duration between studies 6.9 +/- 5.2 months) sleep apnea groups, neither PCO(2) nor cycle length changed significantly between the baseline and follow-up sleep studies. We conclude that in some patients with heart failure, OSA and CSA are part of a spectrum of periodic breathing that can shift over time in association with alterations in PCO(2), cycle length and probably cardiac function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16911035     DOI: 10.1111/j.1365-2869.2006.00528.x

Source DB:  PubMed          Journal:  J Sleep Res        ISSN: 0962-1105            Impact factor:   3.981


  8 in total

Review 1.  Role of nocturnal rostral fluid shift in the pathogenesis of obstructive and central sleep apnoea.

Authors:  Laura H White; T Douglas Bradley
Journal:  J Physiol       Date:  2012-12-10       Impact factor: 5.182

2.  Implications of revised AASM rules on scoring apneic and hypopneic respiratory events in heart failure patients with nocturnal Cheyne-Stokes respiration.

Authors:  Sophia E Schiza; Charalampos Mermigkis; Izolde Bouloukaki
Journal:  Sleep Breath       Date:  2014-07-25       Impact factor: 2.816

3.  eAMI: a qualitative quantification of periodic breathing based on amplitude of oscillations.

Authors:  Helio Fernandez Tellez; Nathalie Pattyn; Olivier Mairesse; Leja Dolenc-Groselj; Ola Eiken; Igor B Mekjavic; P F Migeotte; Em Macdonald-Nethercott; Romain Meeusen; Xavier Neyt
Journal:  Sleep       Date:  2015-03-01       Impact factor: 5.849

Review 4.  Sleep-disordered breathing in heart failure: identifying and treating an important but often unrecognized comorbidity in heart failure patients.

Authors:  Rami Khayat; Roy Small; Lisa Rathman; Steven Krueger; Becky Gocke; Linda Clark; Laura Yamokoski; William T Abraham
Journal:  J Card Fail       Date:  2013-06       Impact factor: 5.712

Review 5.  Diagnostic approaches to respiratory sleep disorders.

Authors:  Renata L Riha
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

Review 6.  Upper airway mechanics.

Authors:  Johan A Verbraecken; Wilfried A De Backer
Journal:  Respiration       Date:  2009-05-29       Impact factor: 3.580

7.  Validation of an apnea and hypopnea detection algorithm implemented in implantable cardioverter defibrillators. The AIRLESS study.

Authors:  Pascal Defaye; Monique Mendelson; Renaud Tamisier; Peggy Jacon; Sandrine Venier; Nathalie Arnol; Jean-Louis Pépin
Journal:  Sci Rep       Date:  2019-07-03       Impact factor: 4.379

Review 8.  Sleep-disordered breathing in patients with heart failure: new trends in therapy.

Authors:  Anna Kazimierczak; Paweł Krzesiński; Krystian Krzyżanowski; Grzegorz Gielerak
Journal:  Biomed Res Int       Date:  2013-07-28       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.